CANNABIS SMOKING;
DRUG WITHDRAWAL;
GLAUCOMA;
HUMAN;
INTRAOCULAR PRESSURE;
LOW LEVEL LASER THERAPY;
MEDICAL SOCIETY;
NEUROPROTECTION;
PRIORITY JOURNAL;
REVIEW;
UNSPECIFIED SIDE EFFECT;
GLAUCOMA;
HUMANS;
INTRAOCULAR PRESSURE;
MARIJUANA SMOKING;
PRACTICE GUIDELINES AS TOPIC;
SOCIETIES, MEDICAL;
TETRAHYDROCANNABINOL;
TIME FACTORS;
UNITED STATES;
The ocular hypertension treatment study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma
discussion 829-830
Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713; discussion 829-830.
Reduction of intraocular pressure and glaucoma progression: Results from the early manifest glaucoma trial
Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120:1268-1279.
Flach AJ. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. Trans Am Ophthalmol Soc. 2002;100: 215-222; discussion 222-224.
Flach AJ. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. Trans Am Ophthalmol Soc. 2002;100: 215-222; discussion 222-224.
7
0031772988
Marijuana and glaucoma
Kaufman PL. Marijuana and glaucoma. Arch Ophthalmol. 1998;116: 1512-1513.
Potential roles of (endo)cannabinoids in the treatment of glaucoma: From intraocular pressure control to neuroprotection
Nucci C, Bari M, Spano A, et al. Potential roles of (endo)cannabinoids in the treatment of glaucoma: From intraocular pressure control to neuroprotection. Prog Brain Res. 2008;173:451-464.